Nita L. Seibel

Also affiliated with National Cancer Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.257Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071

Top 59%

0.257DataRank

Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Papers

Driven by 18 papers — median percentile 41. Top paper: “Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group”.

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

Journal of Clinical Oncology(2023)10.1200/jco.22.01815

N/A

1.7DataRank · unranked

89 citations

Mark Krailo, Julia Glade Bender, Allen Buxton, Nadia N. Laack, R. Lor Randall +20 more

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02838

N/A

0.722DataRank · unranked

122 citations

Katherine A. Janeway, David R. Patton, Cynthia L. Winter, Brent Coffey, P. Mickey Williams +16 more

Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS‐5

Cancer(2023)10.1002/cncr.35099

N/A

0.567DataRank · unranked

21 citations

Carly R. Varela, Lindsay A. Renfro, Brett Tornwall, David Dix, Peter F. Ehrlich +13 more

Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3009

N/A

0.518DataRank · unranked

16 citations

Amit J. Sabnis, Paul M. Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Tazemetostat in patients with tumors with alterations in EZH2 or the SWI/SNF complex: Results from NCI-COG Pediatric MATCH trial Arm C (APEC1621C).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10009

N/A

0.464DataRank · unranked

21 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Cancer(2022)10.1002/cncr.34445

N/A

0.406DataRank · unranked

14 citations

Judith G. Villablanca, Barbara Hero, Brian H. Kushner, Keith Wheatley, Klaus Beiske +9 more

Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2

Cancer(2024)10.1002/cncr.35266

N/A

0.402DataRank · unranked

12 citations

Lindsay A. Renfro, Ian Tfirn, Najat C. Daw, John A. Kalapurakal, Peter F. Ehrlich +12 more

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

The Oncologist(2024)10.1093/oncolo/oyae119

N/A

0.363DataRank · unranked

7 citations

AeRang Kim, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps10071

Top 59%

0.257DataRank

Top 59%3 citations

Katherine A. Janeway, Theodore W. Laetsch, Meredith S. Irwin, Elizabeth Alva, Christine A. Pratilas +14 more

Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma

eJHaem(2023)10.1002/jha2.787

N/A

0.165DataRank · unranked

2 citations

Carl E. Allen, Shweta Jain, Brad Kahl, John Leonard, Heather Wasserstrom +4 more

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10007

N/A

0DataRank · unranked

20 citations

Alexander J. Chou, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.10006

N/A

0DataRank · unranked

4 citations

Rajen Mody, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo +14 more

Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad085

N/A

0DataRank · unranked

95 citations

Joanna S. Yi, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +17 more

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10008

N/A

0DataRank · unranked

2 citations

Olive S. Eckstein, P. Mickey Williams, Sinchita Roy‐Chowdhuri, David R. Patton, Brent Coffey +15 more

Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10007

N/A

0DataRank · unranked

3 citations

Katherine A. Janeway, David R. Patton, Jennifer Lee, Brent Coffey, P. Mickey Williams +16 more

Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration

European Journal of Cancer(2025)10.1016/j.ejca.2025.115629

N/A

0DataRank · unranked

4 citations

Susan Chi, Theodore W Laetscht, Lynley V. Marshall, Elizabeth A. Raetz, Rani E. George +34 more

National Cancer Institute (NCI) implementation of the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) broadening clinical trials eligibility criteria.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6518

N/A

0DataRank · unranked

4 citations

S. Percy Ivy, Katherine H Worthington, Jinxiu Zhao, Nita L. Seibel, Grace Mishkin +3 more

Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10523

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney +11 more

Nita L. Seibel

Indexed papers

Top data-sharing exemplar

Papers